Please use this identifier to cite or link to this item:
Title: Prevention of Vitamin K Deficiency Bleeding in Newborn Infants: A Position Paper by the ESPGHAN Committee on Nutrition.
Authors: Mihatsch, Walter A
Braegger, Christian
Bronsky, Jiri
Campoy, Cristina
Domellöf, Magnus
Fewtrell, Mary
Mis, Nataša F
Hojsak, Iva
Hulst, Jessie
Indrio, Flavia
Lapillonne, Alexandre
Mlgaard, Christian
Embleton, Nicholas
van Goudoever, Johannes
ESPGHAN Committee on Nutrition
metadata.dc.subject.mesh: Dose-Response Relationship, Drug
Drug Administration Schedule
Infant Nutritional Physiological Phenomena
Infant, Newborn
Injections, Intramuscular
Practice Guidelines as Topic
Societies, Medical
Vitamin K
Vitamin K Deficiency Bleeding
Issue Date: 2016
Abstract: Vitamin K deficiency bleeding (VKDB) due to physiologically low vitamin K plasma concentrations is a serious risk for newborn and young infants and can be largely prevented by adequate vitamin K supplementation. The aim of this position paper is to define the condition, describe the prevalence, discuss current prophylaxis practices and outcomes, and to provide recommendations for the prevention of VKDB in healthy term newborns and infants. All newborn infants should receive vitamin K prophylaxis and the date, dose, and mode of administration should be documented. Parental refusal of vitamin K prophylaxis after adequate information is provided should be recorded especially because of the risk of late VKDB. Healthy newborn infants should either receive 1 mg of vitamin K1 by intramuscular injection at birth; or 3 × 2 mg vitamin K1 orally at birth, at 4 to 6 days and at 4 to 6 weeks; or 2 mg vitamin K1 orally at birth, and a weekly dose of 1 mg orally for 3 months. Intramuscular application is the preferred route for efficiency and reliability of administration. The success of an oral policy depends on compliance with the protocol and this may vary between populations and healthcare settings. If the infant vomits or regurgitates the formulation within 1 hour of administration, repeating the oral dose may be appropriate. The oral route is not appropriate for preterm infants and for newborns who have cholestasis or impaired intestinal absorption or are too unwell to take oral vitamin K1, or those whose mothers have taken medications that interfere with vitamin K metabolism. Parents who receive prenatal education about the importance of vitamin K prophylaxis may be more likely to comply with local procedures.
metadata.dc.identifier.doi: 10.1097/MPG.0000000000001232
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.